Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VRPX | US
0.04
6.15%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.72
0.68
0.76
0.68
Virpax Pharmaceuticals Inc. a preclinical-stage pharmaceutical company develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm a topical spray film delivery technology for osteoarthritis pain; Probudur an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200 which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans including influenza and SARS-CoV-2; and NobrXiol an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals Inc. was founded in 2016 and is headquartered in Berwyn Pennsylvania.
View LessValue Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
206.4%1 month
153.7%3 months
144.5%6 months
232.9%-
-
0.48
-
-
-0.05
-
-
-
3.53M
3.53M
-
-
-
-
-362.29
6.89
8.41
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.42
Range1M
0.42
Range3M
1.53
Rel. volume
0.80
Price X volume
217.23K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
InMed Pharmaceuticals Inc | INM | Biotechnology | 0.29 | 3.87M | 21.04% | n/a | 7.00% |
Neurotrope Inc | NTRP | Biotechnology | 2.4 | 3.80M | 0.00% | n/a | 0.00% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.0322 | 3.80M | -31.78% | n/a | 461.91% |
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Oragenics Inc | OGEN | Biotechnology | 0.345 | 3.63M | 5.83% | n/a | 0.00% |
Biodexa Pharmaceticals | BDRX | Biotechnology | 5.98 | 3.47M | 4.91% | n/a | 0.00% |
Alaunos Therapeutics Inc | TCRT | Biotechnology | 2.16 | 3.46M | -4.42% | n/a | 0.00% |
QNRX | QNRX | Biotechnology | 0.8646 | 3.44M | 1.72% | n/a | 43.11% |
22nd Century Group Inc | XXII | Biotechnology | 0.105 | 3.30M | 0.10% | n/a | -1072.15% |
Aptevo Therapeutics Inc | APVO | Biotechnology | 0.2389 | 3.21M | 20.35% | n/a | 112.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.05 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.48 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 144.52 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 3.53M | 3.66B | Emerging |